Clinical trial Recruiting at 1 site Interventional Ages 65 and up Men only

Chest pain screening for hidden cardiac amyloidosis

Official title: CHEST-CA: Study of Chest Pain and Hidden Cardiac Amyloidosis

Run by Copenhagen University Hospital, Rigshospitalet · NCT07435168 · Data updated 2026-11-12

We will test whether men over 65 who have chest pain but no coronary artery disease might have hidden cardiac amyloidosis using blood and urine tests, ECG and echocardiography, bone scintigraphy, and sometimes a heart biopsy.

More Cardiac Amyloidosis trials

Quick facts

Study typeInterventional
Ages65 Years and up
SexMen only
Enrollment300 (estimated)
SponsorCopenhagen University Hospital, Rigshospitalet
Academic / other
Locations1 site (Copenhagen)
StatusRecruiting
StartedApril 1, 2024
Main results expectedApril 1, 2027
Study endsApril 1, 2027
Registry record updatedFebruary 27, 2026
Trial IDNCT07435168 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Men over 65 with chest pain who have had a CT coronary angiogram or Rb-PET showing no coronary artery disease and who do not have a prior history of amyloidosis.

Probably not a fit

Patients who are female, younger than 65, have confirmed coronary artery disease on imaging, or already have a diagnosis of amyloidosis are unlikely to benefit from this screening-focused study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective observational study enrolling men older than 65 who present with chest pain but have no evidence of coronary artery disease on CT coronary angiography or Rb-PET. Participants will undergo blood and urine sampling, ECG, transthoracic echocardiography, and bone scintigraphy to look for signs of cardiac amyloid, with endomyocardial biopsy reserved for inconclusive cases. The primary aim is to determine the prevalence of cardiac amyloidosis in this defined chest-pain population. Data collected at Rigshospitalet will inform whether routine screening in similar patients is warranted.

Why it matters

Potential benefit: If successful, the study could identify men with previously unrecognized cardiac amyloidosis earlier, enabling earlier management and appropriate follow-up.

How similar studies have gone: Noninvasive bone scintigraphy for transthyretin cardiac amyloidosis has been validated and prevalence studies in older adults with heart failure or aortic stenosis have shown notable rates, but applying this approach specifically to chest-pain patients without CAD is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

No signs of CAD through Rb-PET and/or CT coronary arteriogram

Exclusion Criteria:

Previous history of amyloidosis

Where it's running

  • Rigshospitalet
    Copenhagen, Denmark
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.